Language:

Dilated cardiomyopathy

The Lancet (British edition), 2017-07, Vol.390 (10092), p.400-414 [Peer Reviewed Journal]

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 22, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)31713-5 ;PMID: 28190577

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Dilated cardiomyopathy
Author: Weintraub, Robert G, Dr ; Semsarian, Christopher, Prof ; Macdonald, Peter, MD
Subjects: Angiotensin ; Arrhythmia ; Cardiology ; Cardiomyopathy ; Cytoskeleton ; Dilated cardiomyopathy ; Drugs ; Enzyme inhibitors ; Heart ; Heart failure ; Heart transplantation ; Immunosuppressive agents ; Internal Medicine ; Medical prognosis ; Muscle contraction ; Mutation ; Myocarditis ; Patients ; Peptidyl-dipeptidase A ; Proteins ; Stem cells ; Thromboembolism ; Transplantation ; Transplants & implants ; Ventricle
Is Part Of: The Lancet (British edition), 2017-07, Vol.390 (10092), p.400-414
Description: Summary Dilated cardiomyopathy is defined by the presence of left ventricular dilatation and contractile dysfunction. Genetic mutations involving genes that encode cytoskeletal, sarcomere, and nuclear envelope proteins, among others, account for up to 35% of cases. Acquired causes include myocarditis and exposure to alcohol, drugs and toxins, and metabolic and endocrine disturbances. The most common presenting symptoms relate to congestive heart failure, but can also include circulatory collapse, arrhythmias, and thromboembolic events. Secondary neurohormonal changes contribute to reverse remodelling and ongoing myocyte damage. The prognosis is worst for individuals with the lowest ejection fractions or severe diastolic dysfunction. Treatment of chronic heart failure comprises medications that improve survival and reduce hospital admission—namely, angiotensin converting enzyme inhibitors and β blockers. Other interventions include enrolment in a multidisciplinary heart failure service, and device therapy for arrhythmia management and sudden death prevention. Patients who are refractory to medical therapy might benefit from mechanical circulatory support and heart transplantation. Treatment of preclinical disease and the potential role of stem-cell therapy are being investigated.
Publisher: England: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(16)31713-5
PMID: 28190577
Source: ProQuest One Psychology
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Dilated cardiomyopathy

Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jul 22, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)31713-5 ;PMID: 28190577

Searching Remote Databases, Please Wait